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Gene expression proﬁling (GEP) of 8 stage 0/I untreated Chronic Lymphocytic Leukemia (CLL) patients showed over-expression
of Frizzled 3 (FZD3)/ROR-1 receptor tyrosine kinase (RTK), FLT-3 RTK and CXCR3 G-protein coupled receptor (GPCR). RT-
PCR of 24 genes in 21 patients of the WNT pathway corroborated the GEP. Transforming growth factorβ, ﬁbromodulin, TGFβRIII
and SMAD2 are also over-expressed by GEP. Serum cytokine proﬁling of 26 low stage patients showed elevation of IFNγ, CSF3,
Flt-3L and insulin-like growth factor binding protein 4. In order to ascertain why CLL cells grow poorly in culture, a GEP of
4 CLL patients cells at 0 hr and 24 hr in culture demonstrated over expression of CXCL5, CCL2 and CXCL3, that may recruit
immune cells for survival. Treatment with thalidomide, an immunomodulatory agent, showed elevation of CCL5 by GEP but was
not cytotoxic to CLL cells. Our data suggest an interplay of several oncogenic pathways, cytokines and immune cells that promote
a survival program in CLL.
Copyright © 2009 Daruka Mahadevan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most
common adult leukemia in the Western world. CLL cells
express 1 or more B cell associated antigens, generally CD19,
CD20 and CD23 with coexpression of CD5, a T cell marker
[1, 2]. Fluorescent in Situ Hybridization (FISH) for speciﬁc
karyotypicmarkers[3]andpolymerasechainreaction(PCR)
for immunoglobulin heavy chain variable region (IgVH)
gene mutations [4, 5] provide prognostic information. An
association between IgVHgene mutation and CD38 expres-
sion has been observed [6]. Increased CD38 expression
has been correlated with the unmutated state [6]. The 70
kDa zeta-associated protein (ZAP-70) a cytoplasmic tyrosine
kinase measured by ﬂow cytometry [7, 8]o rb yR T - P C Ra n d
immunohistochemistry (IHC) [9], appears to improve the
prognostic signiﬁcance of cytogenetics and IgVHmutational
status. CLL patients who are ZAP-70 positive irrespective of
their clinical stage, cytogenetics and IgVH mutational status
have a shorter progression free survival [10].
Several groups have performed gene expression proﬁling
(GEP) on CLL [11–16] to establish a gene expression
signature, prognostic groups, cell of origin, correlation
with genomic defects and diagnostic markers. These studies
provide evidence that the CLL GEP is related to memory B-
cells. Further, there appears to be a correlation between GEP2 Human Genomics and Proteomics
and genomic loss or gain suggesting that gene dosage may
be important to CLL pathogenesis [11, 17]. More recently
microRNA (miRNA) expression proﬁles have been utilized
to distinguish normal B-cells from CLL cells and provide a
signature that is associated with prognosis and progression
[18]. The WNT/FZD canonical pathway has been proposed
as a possible mechanism of oncogenesis in CLL [19–21].
ROR-2, a close member of ROR-1, has been shown to bind
Wnt-5A via the cysteine rich domain (CRD) and to activate
the JNK signaling pathway [22].
Current treatments cannot cure CLL and more eﬀective
therapies based on abrogating key oncogenic signaling
pathways are needed. Here, we pose several key objectives
and goals to address this statement by utilizing gene expres-
sion and cytokine proﬁling of Rai stage 0/I CLL patients
which include, (A) What are the diﬀerentially expressed
genes in CLL? Previous studies used a microarray platform
containing fewer genes, and therefore the current study with
>10,000 novel genes would likely yield novel diﬀerentially
expressed genes, (B) What oncogenic signaling pathway(s)
are likely to drive CLL progression?, as they may help
identify parallel cross-talking pathways, (C) What serum
cytokines are associated with immune evasion and survival?,
that may activate CLL and/or stromal cells , (D) What
are the six hallmarks of cancer for CLL and can they be
targeted rationally?, (E) What is the status of p53 and
ZAP-70 in low stage CLL?, since both are associated with
a poor prognosis, (F) Does GE change when CLL cells
are cultured for a given time? This would address the
important question of why it is diﬃcult to grow CLL cells in
culture and help identify diﬀerentially expressed genes after
treatment with drugs (e.g., thalidomide, an immunomod-
ulatory agent). Based on GEP studies we identiﬁed over-
expression of members of the non-canonical WNT/PCP-
ROR-1 signaling pathway genes that were validated by RT-
PCR. Two other pathways (CXCL9/CXCR3 and Flt3L-Flt-
3 RTK) were identiﬁed where both ligand serum levels
and cognate receptors, on CLL cells, were elevated. We
show that the majority of the patients diﬀerentially over-
expressed ZAP-70 while p53 was down regulated. The
GEP of CLL cells at 0 hours and 24 hours in culture
showed diﬀerential over-expression of the cytokine CXCL5.
Treatment of CLL cells with thalidomide, a potent anti-
angiogenic and immunomodulatory drug, had no eﬀect
on cell viability but led to the over-expression of cytokine
CCL5. Together, these results provide novel biological
insights and potential therapeutic targets for low-stage CLL
patients.
2.MaterialsandMethods
2.1. Reagents. Isolated and puriﬁed CLL cells from patients
were cultured in 10% human serum albumin (Gemini Bio-
Products, Woodland, CA) in RPMI-1640 media. Polyclonal
antibodies to FZD3 (R&D Systems, MN), ROR-1 (R&D
Systems, MN) and Flt-3 (Santa Cruz, CA) were obtained.
Secondary antibody at a 1 : 5000 dilution (IRDyeTM 800
donkey anti-rabbit, Rockland Immunochemicals) was used
to visualize bands with a LI-COR Odyssey Infrared Imaging
System. Thalidomide powder (Sigma) was freshly dissolved
in dimethyl sulphoxide (DMSO) at a 5mM stock solution
and diluted into RPMI-1640 media with 10% human serum
immediately prior to use. CD19+ normal PB B-cell RNA
from 4 normal volunteers was purchased from AllCells, CA.
2.2. Patient Samples and Preparation. All patients studied
had a diagnosis of CLL stage 0 or I. Patient blood samples
(N = 26) were collected after obtaining informed consent
on an Institutional Review Board approved protocol. Whole
blood was collected for cells and serum. Mononuclear
cells were separated and either stored frozen at −80◦C
or maintained in RPMI-1640 medium with 10% human
serum (Gemini BioProducts, CA) at 37◦Ci n5 %C O 2.
Separated serum was stored in 0.5mL aliquots at −80◦C
untilfurtherstudieswereperformed.Mononuclearcellswere
separated from peripheral blood samples by Ficoll-Hypaque
density centrifugation [12] and phenotype was determined
by immunoﬂuorescent ﬂow cytometry analysis [13]. The
CLL cells were then maintained in culture in RPMI-1640 at
37◦C for further studies.
2.3. RNA Isolation and Aﬀymetrix Microarrays. Total RNA
was extracted using the RNeasy Mini Kit (Qiagen, CA)
from 8 patient CLL cells at collection. Further, RNA was
extracted from 4 patient CLL cells in culture for 24 hours
and after treatment with thalidomide (1μM) for 24 hours.
The amount of total RNA isolated from the cells was
quantiﬁed using spectrophotometric OD260 measurements
with yields≥25μg/sample. Control RNA was obtained from
normal peripheral (PB) B-cells from 4 volunteers (AllCells,
CA). 5μg of mRNA was used to generate ﬁrst-strand cDNA
by using a T7-linked oligo(dT) primer. After second-strand
synthesis, in vitro transcription (Ambion) was performed
with biotinylated UTP and CTP (Enzo Diagnostics), result-
ing in 40- to 80-fold linear ampliﬁcation of RNA. 40μg
of biotinylated RNA was fragmented to 50- to 150-nt
size before overnight hybridization at 45◦C to HG-U133A
2.0 Aﬀymetrix array comprising ∼18,400 transcripts and
22,000 probe sets (Santa Clara, CA). After washing, arrays
were stained with streptavidin—phycoerythrin (Molecu-
lar Probes) and scanned on a Hewlett-Packard scanner.
Intensity for each feature of the array was captured by
using GENECHIP SOFTWARE (Aﬀymetrix, CA), and a
single raw expression level for each gene was derived
from the 10-20 probe pairs representing each gene by
using a trimmed mean algorithm. Intensity values were
scaled such that overall intensity for each chip of the
same type was equivalent. After hybridization, the quality
of the data was tested with several methods. The arrays
were ﬁrst inspected visually for artifacts and B2 Oligo
performance per manufacturer’s instructions (Aﬀymetrix,
Inc. “Gene Chip c  Expression Analysis Technical Manual”,
November 2004). Chip CEL ﬁles were then imported
into R-BioConductor (v. 1.7) (http:// genomebiology.com/
2004/5/10/R80). MAS5 Present/Absent calls were gen-
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.ac.uk/simpleaﬀy/) package using a target scaling factor of
100. The scale factors were within 3-fold of each other as
recommended in the guidelines provided in the Aﬀymetrix
Gene Chip c  Expression Analysis: Data Analysis Funda-
mentals manual. The quality control metrics were generated
using the “qc” function provided in the simpleaﬀy package.
All chips performed as follows: the average backgrounds
fell between 20 and 100, hybridization controls (bioB,
bioC, bioD and cre) were all called present with increasing
signal intensities and the 3 /5  ratios for the internal
controls (GAPDH and β-actin) were less than 1.25 and 3
respectively. Further quality control was performed using
the aﬀyP L Mpackage provided in the BioConductor suite.
The microarray data were normalized by robust multi-
chip analysis (RMA) using the “ﬁtPLM” function (default
values). Chip pseudo-images of the weights and residuals,
normalized unscaled standard error (NUSE) and relative
log expression (RLE) values were used for chip-level quality
assessment. Chip pseudo-images displayed no apparent
artifacts that warranted excluding a chip from further
analysis. NUSE and RLE plotting revealed the chips used
in the experiments to be consistent. Next, chips were
normalized by RMA using the simpleaﬀy package. Log-fold
changeswerecalculatedfromthenormalizedlog2expression
values.
2.4. Gene Expression Data Analysis and Visualization. For
each CLL sample at collection, in culture for 24 hours or
treated with thalidomide for 24 hours a comparison to
the control samples (normal B-cells) and lists of ‘robust
increasers’ or ‘robust decreasers’ was generated utilizing
the Aﬀymetrix Data Analysis Program (Aﬀymetrix MAS
5.0). Fundamentals’ guide was used to import these lists
into GeneSpring (version 5.0) and obtain the intersec-
t i o no fr o b u s ti n c r e a s e r so rd e c r e a s e r sa c r o s sa l lp a t i e n t s .
Increasers or decreasers common to CLL patients were
compared to normal PB B-cells. In order to assess quality
and reproducibility of our data, we leveraged published
independent global GEP studies of CLL for robust increasers
and decreasers. GEP for each patient was further classiﬁed
according to the hallmarks of cancer [23], to determine CLL
speciﬁc ‘tumor proﬁle signatures’. Intersection of the gene
lists for each target with the commonly up-regulated and
down-regulated genes across patient samples was obtained.
This was also performed on the intersects of the up-
and down-regulated gene lists with the GeneSpring “Sim-
pliﬁed GO Ontology” as another method of classifying
genes.
2.5. Real Time Quantitative RT-PCR. One hundred
nanograms of total RNA were used for reverse transcriptase
(RT) reactions (20 ml total volume) carried out using
SuperScriptTM III Platinum Reverse Transcriptase
(Invitrogen, Carlsbad, CA). Reactions were incubated
at 42◦C for 50 minutes followed by incubation at 37◦C
with RNase H for 20 minutes. An Opticon DNA Engine
(MJ Research, Reno, NV) was used to perform real-time
ﬂuorescence detection PCR. 1μl cDNA was added to
12.5μl of Platinum SYBR Green qPCR SuperMix-UDG
(Invitrogen, Carlsbad, CA), 1μl of gene-speciﬁc or β-actin
speciﬁcprimerpair(seeprimerdesign),and10.5μlofdH2O
(ﬁnalvolumeof25μl).Ampliﬁcation(95◦Cfor15s,55◦Cfor
30s, and 72◦C for 30s) was repeated for 44 cycles. Threshold
cycle value (Ct) for each sample indicated the cycle at which
a statistically signiﬁcant increase in ﬂuorescence was ﬁrst
detected. These data were then normalized to β-actin, which
served as an unaﬀected control gene, for each data point and
compared to a normal B-cell control to determine relative
expression ratios. Each measurement was performed in
triplicate.
2.6. Primer Design. PCR primers were designed using
MacVector (Accelrys, San Diego, CA) to produce ampli-
cons with lengths ranging from 80-250 bp to optimize the
eﬃciencyofqPCR.β-actinprimersfromQuantumRNATMβ-
Actin Internal Standards (Ambion, Austin, TX) were used to
normalize the qPCR data. The following genes were analyzed
by real time quantitative RT-PCR: AXIN1, BLK, CSN1A1,
CTNNB1, DVL1, FRAT1, FZD3, FZD6, FLT-3, GSK3 β,I T K ,
JAK2, JUN, LEF-1, MAPK10, MAPK8, MAPK9, PRKCB1,
ROR-1, ROR-2, SYK, TCF4, P53, WNT-3A, WNT-5A and
ZAP70.
2.7. Serum Cytokine Proﬁling. Stored (−80◦C) or fresh
patient serum samples were utilized (N = 26 patients).
Array slides were thawed at room temperature as serum was
diluted 3.5-fold with 1x blocking buﬀer (Cytokine Array
Protocol, RayBiotech, Inc #AAH-CYT-G1000). Slides were
blocked with blocking buﬀer and 50μLo fe a c hs a m p l e
was hybridized with the slide for 2 hours; 1μL internal
controls were also added. After washing, provided biotin-
conjugatedanti-cytokineantibodiesweredilutedwith300μL
of blocking buﬀer, added to the slide, and incubated for 2
hours at room temperature. Washing steps were repeated,
followed by addition of a 1:1500 dilution of Alexa Flour
555-conjugated streptavidin and incubated overnight at 4◦C.
Slides were washed multiple times and read on the Axon
GenePixusingthecy3channel.Analysiswasconductedusing
the RayBiotech analysis tool.
2.8. Immunoprecipitation and Immunoblotting. CLL cells
were lysed with 1% Nonidet P-40 lysis buﬀer. 500μg clariﬁed
lysate per sample was incubated at 4◦C overnight with anti-
ROR-1 polyclonal antibodies followed by the addition of
protein A agarose (Upstate Biotechnology) for a further
2 hours. After PAGE and transfer to Immobilon mem-
branes (Millipore, MA), immunoblotting was performed
using the anti-ROR-1 antibody. Alternatively, 50–100μgo f
p r o t e i nf r o mc e l le x t r a c t sw a ss e p a r a t e db yP A G Ea n d
immunoblotted with protein-speciﬁc antibodies. Protein
bands were visualized utilizing the secondary antibody at a
1 : 5000 dilution (IRDyeTM 800 donkey anti-rabbit, Rock-
land Immunochemicals) with a LI-COR Odyssey Infrared
Imaging System.4 Human Genomics and Proteomics
3. Results
3.1. Gene Expression Proﬁle of Stage 0/I CLL. The purity of
the CLL samples estimated from the percentage of CD19
cells was at a mean of 89% (range 80–95%) (Supplementary
Figure 1. Please see in supplementary materials avilable
online at doi:10.1155/2007/453634) which is very similar
to that described by Stratowa et al. [13]. A GEP was
conducted on 8 low stage CLL patients, 4 normal volunteers
without age-matched CD19+ B-cells (AllCells, CA) utilizing
the Aﬀymetrix platform (22,000 genes) with >10,000 genes
than previously published GEP studies. We compared the
most signiﬁcantly over-expressed and down-regulated genes
of CLL versus normal B-cells in our GEP to that of
Klein et al. 2001 [12] (U95A Aﬀymetrix microarray) and
Jelinek et al. 2003 [17] (U95Av2 Aﬀymetrix microarray). Ten
distinct genes represented by 15 probe sets were diﬀerentially
expressed in all three studies (Table 1). Moreover, 46 [12]
and 55 genes [17] also matched our data set. Hence, our
data validate and add to the current knowledge on CLL
GEP studies. An analysis of diﬀerentially expressed genes
by fold change between CLL versus normal PB B-cells was
performedinagene-by-geneanalysisfordiﬀerencesbetween
the2groups. Genes thatare“robustly”highly over-expressed
or down regulated that are common to all 8 CLL patients
were compared to normal PB B-cells. For brevity only
the 20 top over-expressed (Table 2(a)) or down regulated
(Table 2(b)) genes are shown. Of the over-expressed genes
(Table 2(a)), 5 are listed in Table 1 (ABCA6, ﬁbromodulin,
LEF-1, IGFBP4, RASGRF1) conﬁrming the data from Klein
et al., 2001[12] and Jelinek et al., 2003 [17]. Novel over-
expressed genes from this study are HBA, HBB, PDGF-DD,
ROR-1, FRY, SELP, HLA-DQA1 and VIPR1 all of which
are implicated in human malignancies including leukemia,
lymphoma and solid tumors. It appears that the comparison
of CLL patients to normal PB B-cells demonstrates that
several of the diﬀerentially genes are represented within
the 6 hallmarks of cancer [23]. For CLL they are tumor
invasion (COL9A2, RAPGEF3, SPOCK2, WNT3, CORO1B,
CCL5, IL2RB, MAP2K6), anti-apoptosis and survival (LEF1,
IGFBP4, ROR-1, MYBL1, PIM-1, LCK, FLT-3), cell cycle
deregulation (PFTK1, PLK3) and angiogenesis (PDGF-DD,
FGF2). Consistent with CLL several of the Ig gene family
members (light chain variable and heavy chain constant)
are the most highly down regulated. Other highly down
regulated genes of signiﬁcance to tumor biology include
CCR6, BCL7A, MYC, MAFB, CASP2 and HSP70B.
3.2. Serum Cytokine Proﬁle (SCP) of CLL Patients. Serum
samples from 26 CLL patients and 4 normal volunteers were
analyzed utilizing the cytokine array G-1000 platform con-
sisting of 120 cytokines/chemokines/growth factors (RayBio,
GA). Fold change was calculated for each patient, corrected
forabsolutelymphocytecountandamean±SDobtainedfor
each cytokine for all patients. The mean fold change of ≥6-
fold are shown in Table 3(a). Our cytokine proﬁle identiﬁed
all of the published elevated cytokines associated with CLL
cell survival (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF ,I F N γ
or  , G-CSF or GM-CSF) or inhibition (IL-5, TGFβ)[ 24].
Table 1: The most signiﬁcantly over-expressed and down regulated
genes representative in CLL versus normal PB B-cells in our
GEP (HG-U133A Aﬀymetrix array) compared to that of Klein et
al. (12; U95A Aﬀymetrix array) and Jelinek et al. (15; U95Av2
Aﬀymetrix array). The 10 distinct genes represented by 15 probe
sets diﬀerentially expressed in all three CLL GEP studies with fold
change.
Gene Name Fold Change
ABCA6
ATP-binding cassette,
subfamily A(ABC1),
member 6
151
COL9A3 Collagen, type IX, alpha
3
9
FMOD Fibromodulin 142
IGFBP4 Insulin-like growth
factor binding protein 4
63
LEF1
Lymphoid
enhancer-binding factor
1
92
RASGRF1
Ras protein-speciﬁc
guanine
nucleotide-releasing
factor 1
25
TGFbR3
Transforming growth
factor, beta receptor III
(beta glycan, 300kDa)
3
MYC
v-Myc myelocytomatosis
viral oncogene homolog
(avian)
−12
SORL1
Sortilin-related receptor,
L(DLR class) A repeats-
containing
−8
TKT
Transketolase
(Wernicke-Korsakoﬀ
Syndrome)
−3
In our cytokine proﬁle the 1st ranked is IFNγ (14.46 fold)
which is well known to prevent apoptosis of CLL cells. The
2nd ranked is IGFBP-4 (14.22 fold) and of signiﬁcance is
that it is also over-expressed in the GEP indicating that
serum levels reﬂect CLL production of this cytokine. The
function(s) IGFBP-4 are not well characterized except for
binding IGF-I and IGF-II. In most human malignancies
IGFBP-4 is expressed at levels which appear to correlate
with their state of diﬀerentiation [25]. The 3rd ranked
is G-CSF (10.89 fold) which is known to decreases CLL
cell apoptosis. The 4th ranked is IL-3 (8.45 fold) which
provides a proliferative signal to CLL cells especially during
the lymphoblastoid phase [26]. Other signiﬁcantly increased
serum cytokines are Flt-3 ligand (7.82 fold), SCF (6.76 fold)
and SDF-1 (6.54 fold).
3.3. Identiﬁcation of a G-Protein Coupled Receptor and Recep-
tor Tyrosine Kinase Pathways in CLL. Utilizing both the GEP
and SCP, an analysis of ligand-receptor (L-R) pairs of the
cytokine-cytokine receptor or growth factor-growth factor
receptor (PDGF, TNF, TGFβ, WNT) that are simultaneously
elevated in our cohort of CLL patients were analyzed
utilizing the KEGG database (http://www.genome.jp/kegg/).Human Genomics and Proteomics 5
Table 2: (A). The top 20 over-expressed genes; (B). The top 20 down regulated genes.
ID Symbol Name Fold Change
A 217232 x at HBB hemoglobin, beta 188.0
217414 x at HBA2 hemoglobin, alpha 2 178.6
214414 x at HBA1 hemoglobin, alpha 1 163.3
217504 at ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 150.6
202709 at FMOD ﬁbromodulin 142.4
221558 s at LEF1 lymphoid enhancer-binding factor 1 92.1
221078 s at KIAA1212 KIAA1212 76.4
204135 at DOC1 NA 70.1
201508 at IGFBP4 insulin-like growth factor binding protein 4 63.4
222154 s at DNAPTP6 NA 47.1
205414 s at KIAA0672 NA 45.4
219304 s at PDGFD platelet derived growth factor D 36.2
205805 s at ROR1 receptor tyrosine kinase-like orphan receptor 1 34.8
219387 at KIAA1212 KIAA1212 34.8
204072 s at FRY furry homolog (Drosophila) 34.0
206049 at SELP selectin P (granule membrane protein 140kDa, antigen CD62) 33.7
213831 at HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 33.4
205019 s at VIPR1 vasoactive intestinal peptide receptor 1 32.3
210550 s at RASGRF1 Ras protein-speciﬁc guanine nucleotide-releasing factor 1 24.7
B 221530 s at BHLHB3 basic helix-loop-helix domain containing, class B, 3 −52.6
211635 x at IGHV1-69 immunoglobulin heavy variable 1-69 −52.9
219049 at ChGn NA −60.2
211639 x at NA NA −68.3
211798 x at IGLJ3 Immunoglobulin lambda joining 3 −74.2
214973 x at IGHD Immunoglobulin heavy constant delta −90.9
211637 x at NA NA −93.7
203038 at PTPRK Protein tyrosine phosphate, receptor type, K −93.9
211645 x at NA NA −97.7
200606 at DSP Desmoplakin −98.9
217227 x at NA NA −109.0
211644 x at IGKC Immunoglobulin kappa constant −119.3
211650 x at NA NA −126.9
216491 x at IGHM Immunoglobulin heavy constant mu −133.0
210432 s at SCN3A Sodium channel, voltage-gated, type III, alpha −153.6
214777 at NA NA −192.3
216984 x at IGLC2 Immunoglobulin lambda constant 2(kem-Oz-marker) −194.3
214768 x at IGKV1-5 Immunoglobulin kappa variable 1-5 −247.1
216510 x at IGHA1 Immunoglobulin heavy constant alpha 1 −288.4
217148 x at IGLV3-25 Immunoglobulin lambda variable 3-25 −433.5
Several L-R pairs were identiﬁed as signiﬁcantly over-
expressed. Table 3B highlights several of these L-R pairs
with their respective fold changes and known function(s).
We identiﬁed 3 major oncogenic signaling pathways:
GPCR CXCL9/CXCR3 pathway; and the RTK pathways of
WNT/FDZ3-ROR-1PCPandFlt-3L/FLT-3.Previously,ithas
been shown that CXCR3 is expressed on CLL cells [27]
and may play a role in chemotaxis. Moreover, the CXCR3
ligand, CXCL9, is coexpressed in CLL cells [28] implicating
an autocrine mechanism of activation. Our data conﬁrm
these individual observations, extend the ﬁnding that low
stage CLL patients express both CXCL9 and CXCR3 that
may promote immune mediated cell homing in addition to
chemotaxis.
The expression and activation of the classical WNT/FZD
signaling cascade has been implicated in CLL. Lu et al.,
2004 [19], quantiﬁed the GEP of the WNT family and their
cognate FZD receptors in CLL cells, and determined the
role of WNT signaling in promoting CLL cell survival. Our
GEP identiﬁed ROR-1 RTK to be over-expressed, which6 Human Genomics and Proteomics
Table 3: Serum cytokine proﬁle of 26 CLL patients with ≥6-fold change compared to 4 normal volunteers and SCF identiﬁed several ligand-
receptor (L-R) pairs of the chemokine, cytokine, and growth factor receptor pathways. In parenthesis are the fold changes for each of the L-R
pairs and known function(s) of the pathway.
(a)
Cytokine Fold Change Function(s)
IFNg 14.463 Antiviral; activates macrophages
IGFBP-4 14.217 Alters IGF interaction with receptors
G-CSF 10.894 Control white cell population
IL-3 8.446 Growth & diﬀerentiation; histamine release
PIG-F 8.361 GPI-anchor biosynthesis
TNFb 8.074 Phagocytosis and cell death
IL-6 8.052 B-cell diﬀerentiation
IGF-I 7.543 Regulates somatic growth and proliferation
IL-13 7.509 Inhibits inﬂammatory cytokine production
MCP-1 7.220 Monocyte recruitment and attraction
Flt-3L 7.021 Stimulates hematopoietic cell production
SCF 6.764 Stimulates mast cell production
SDF-1 6.538 Chemoattractant for monocytes & T-cells
FGF-6 6.484 Stimulates mitogenesis and angiogenesis
BMP-6 6.206 Induces bone & cartilage formation
(b)
Ligand (Fold D) Receptor (Fold D) Function(s)
CXCL9 (5-fold) CXCR3 (2.5-fold) Chemotaxis (24)
WNT-3 (8-fold) FDZ3 (3-fold) Cell Survival (18)
WNT-16 (2-fold) ROR-1 (35-fold)
Flt-3L (7-fold) FLT-3 (7-fold) Cell Survival & Proliferation
IL-2 (5.3-fold) IL-2RA (3.3-fold) Proliferation (48)
IL-15 (5.4-fold) IL-2RB (6-fold)
IL-7 (4.6-fold) IL-7R (6.7-fold) Immunological Dysregulation (49)
IL-10 (6-fold) IL-10RA (2.7-fold) Growth Factor (50)
TNF (8-fold) SF1A (3-fold) Apoptosis & NF-kappa-B
LTA (4.6-fold) signaling
is a member of the non-canonical WNT/PCP pathway.
The coreceptor of ROR-1, FZD3 and FZD6 are also over-
expressed implicating the activation of the WNT non-
canonical pathway in CLL (Table 3(b)). Hence, we analyzed
20 representative members of the canonical and non-
canonical pathway from the cell membrane to the nucleus
by quantitative real time RT-PCR to ascertain which pathway
was active in CLL. The members of the canonical path-
way are down regulated (DVL1, AXIN, GSK-3β, TCF-1)
except for LEF-1 (Figure 1), while members of the non-
canonical pathway are over-expressed (ROR-1, FZD3, JAK2,
JNK2, ITK) (Figure 2). GEP identiﬁed over-expression of
several members of the non-canonical pathway: WNT3
(8-fold), WNT16 (2-fold), FZD3 (3-fold), FZD6 (2-fold)
and PCKε (7-fold) to be over-expressed. Western blotting
analyses performed on 4 representative CLL patient cells
for Ror-1 conﬁrmed expression at the protein level (Sup-
plementary Figure 2). These studies provide evidence for
importance of the WNT-ROR-1 non-canonical pathway in
CLL.
The SCP and GEP identiﬁed Flt-3L to be elevated
(serum) and FLT-3 to be over-expressed (microarray) in all 8
CLL patients. RT-PCR of 20 CLL patients for FLT-3 showed
that 8 (40%) had over-expression while 12 (60%) had no
change in expression (Supplementary Figure 3). We next
searched for downstream signaling molecules associated
withFlt-3activationandidentiﬁedover-expressionofPIM-1
(8-fold)(proviralinsertionalmutagenesis-1serine/threonine
kinase) and c-MYB (4-fold) proto-oncogenes. This novel
ﬁnding implicates activation of the FLT-3 RTK pathway in
a subset of CLL that may contribute to cell survival. In acute
myeloid leukemia (AML), FLT-3 signaling up-regulates
PIM-1 expression and activation [29]b u ts u c har o l eh a s
not been previously described for CLL. Hence, our ﬁnding
of coexpression of Flt-3L and FLT-3 L-R pair is novel and
requires further investigation.
3.4. Status of P53 and Zap70 in Low Stage CLL Patients.
Both ZAP-70 and P53 have been demonstrated to beHuman Genomics and Proteomics 7
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Figure 1: Quantitative real time RT-PCR on 21 low stage CLL patients for selected genes of the WNT/FDZ canonical pathway where key
members are down regulated except for LEF-1.
important prognostic factors in CLL. In a subset of CLL
patients with 17p deletion where p53 is lost an aggressive
chemo-resistant clinical course ensues. ZAP-70 expression
apparently identiﬁes a CLL subtype with an inferior clinical
outcome. We conducted quantitative real time RT-PCR on
21 low stage CLL patients for ZAP-70 and P53 expression
(Supplementary Figure 4). The results show that P53 is
down-regulated in almost all patients, while ZAP-70 is over-
expressed in 18 of 21 patients. It is possible that a small
fraction of contaminating normal T-cells in the puriﬁed
CLL samples may aﬀect the ZAP-70 RT-PCR data, however
the diﬀerential expression observed by GEP suggests this is
minimal. Thedown regulationofp53 expression inlow stage
CLL appears to be an early event in the oncogenic program.
3.5. Diﬀerential Gene Expression of CLL Cells at 24 Hours in
Culture. It is an enigma as to why CLL cells puriﬁed from
patients are not amenable to medium and long term cell
culture. These predominantly mature malignant B-cells are
resistant to apoptosis but once in cell culture lose viability.
A key goal of the study was to identify factor(s) that may
contribute to loss of viability and diﬀerential gene expression
by GEP was utilized to investigate this phenomenon. A GEP
study of 4 CLL patients at 0 hours and at 24 hours in
culture showed several genes to be diﬀerentially expressed at
24 hours (Supplementary Table 1). The chemokine CXCL5
was ∼120 fold over-expressed followed by several other
chemokines, CCL (2, 3 and 23) and CXCL (1, 2 and 3)
subtypes. Interleukins-1 (α and β), IL-6 and IL-8 were also
over-expressed.
3.6. Thalidomide is not cytotoxic and induces modest GEP
changes. The iMiDs thalidomide and lenalidomide are
currently under evaluation as potential novel agents in
Phase I trials in CLL (24). We investigated the eﬀect
of thalidomide on the diﬀerential gene expression of 4
CLL patient cells treated in culture for 24 hours. Since
there were gene expression changes at 24 hours in culture
without thalidomide therapy, these changes were taken
into account when analyzing the eﬀects of thalidomide on
changes in gene expression. Cell viability studies indicated
thalidomide was not cytotoxic to CLL cells (data not shown).
Thalidomide induced modest diﬀerential gene expression
changes(SupplementaryTable2),withCCL5 ∼2.5foldover-
expressed.
3.7. Discovery of New Therapeutic Targets. Our study also
analyzed potential therapeutic targets that may be amenable
to targeting either with small molecular inhibitors and/or
monoclonal antibodies. For patients with CLL the following
are novel targets: small molecular inhibitors to protein
kinases (ROR-1, Flt-3, ZAP-70, PIM-1, LCK PFTK1, PLK-
3), monoclonal antibodies to circulating ligands (CXCL9,
IGFBP4, Flt-3 ligand, PDGF-DD, FGF2) and monoclonal
antibodies to cell surface receptor (FZD3, Flt-3, ROR-1,
CXCR3).8 Human Genomics and Proteomics
13 579 1 1 1 3 1 5 1 7 1 9
Patients
ROR1
−200
−150
−100
−50
0
50
100
150
200
250
300
F
o
l
d
c
h
a
n
g
e
(a)
13 579 1 1 1 3 1 5 1 7 1 9
Patients
FZD3
−4
−2
0
2
4
6
8
10
12
F
o
l
d
c
h
a
n
g
e
(b)
13 579 1 1 1 3 1 5 1 7 1 9
Patients
JAK2
−8
−6
−4
−2
0
2
4
6
F
o
l
d
c
h
a
n
g
e
(c)
13579 1 1 1 3 1 5 1 7 1 9 2 1
Patients
ITK
−4
−2
0
2
4
6
8
10
12
14
F
o
l
d
c
h
a
n
g
e
(d)
13579 1 1 1 3 1 5 1 7 1 9 2 1
Patients
JNK-2(MAP3K9)
−3
−2
−1
0
1
2
3
4
5
F
o
l
d
c
h
a
n
g
e
(e)
Figure 2: Quantitative real time RT-PCR on 21 low stage CLL patients for selected genes of the WNT/PCP non-canonical pathway where
key members are over-expressed.
4. Discussion
We undertook a gene expression and serum cytokine proﬁle
study of low stage CLL patients to glean biological insights
into disease pathogenesis. First, our data conﬁrmed the key
GEP ﬁndings of Klein et al., 2001[12] and Jelinek et al.,
2003 [17] and signiﬁcantly adds to current knowledge of
CLL biology. Second, we identiﬁed several signiﬁcantly over-
expressed novel genes that enhance further diﬀerentiation of
CLL from normal circulating PB B-cells. This has allowed
an extension of the molecular signature proﬁle based on
the six hallmarks of cancer [23] for CLL. Third, a serum
cytokine proﬁle of 26 CLL patients show several elevated
cytokines/growth factors that are novel and help identify
ligand-receptor pairs that may be pertinent to CLL biology.
Finally, quantitative real time RT-PCR and Western blotting
analyses of key genes and proteins respectively were utilized
to validate and conﬁrm the GEP.
The WNT/FDZ3-ROR-1 PCP non-canonical pathway is
over-expressed in CLL cells. The PCP signaling pathway
controls tissue polarity and cell movement through activa-
tion of RhoA, c-Jun N-terminal kinase (JNK), and nemo-
like kinase (NLK). Human Wnt5A, Wnt5B, and Wnt11
are non-canonical Wnt ligands that transduce PCP signals
through FZD3 or FZD6 receptors, and coreceptors ROR-
1, ROR-2 or PTK7. The aberrant activation of WNT/PCP
signaling pathway leads to a malignant phenotype with
associated abnormal tissue polarity, invasion, and metastasis
[30]. Previously, Lu et al., 2004 [19], provided evidence
for the WNT/FZD canonical pathway as a possible mech-
anism of oncogenesis and cell survival in CLL. RT-PCR of
both the canonical and non-canonical pathway members,
conﬁrmed down regulation of the WNT/FDZ canonical
pathway (DLV1, AXIN, FRAT-1, GSK-3β, β-CATENIN,
TCF) except for LEF-1 which was over-expressed in allHuman Genomics and Proteomics 9
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Figure 3: Schematic representation of four novel signaling pathways that may contribute to the malignant phenotype observed in early stage
CLL.
patients (Figure 1). Over-expression of LEF-1 in CLL cells
has been described [12, 17, 19] and appears to play a role
in pro-B cell development but not in mature B-cells [31].
In contrast, we found that FZD3 to be over-expressed and
FZD6 to be down-regulated, while their coreceptor Ror-1
and JNK-2 of the WNT/PCP pathway are over-expressed
(Figure 2). ROR-1 is a neural developmental kinase (937
amino acids) [32] but its cellular role has not been fully
characterized. A truncated ROR-1 is found to be expressed
in human leukemia and lymphoma cell lines and in several
human neuroectodermal malignancies [33]. A mechanism is
proposed for activation of the FZD3-ROR-1 PCP pathway
(Figure 3) via Wnt binding to the Ror-1 CRD [34]. Thus
a switch from WNT/FZD canonical to WNT/PCP non-
canonical signaling in CLL is proposed.
Although key members of the WNT/FZD canonical
pathway are down regulated in CLL, LEF-1 is over-expressed.
This discrepancy may be due to expression and activation
of LEF-1 via an alternative signaling pathway(s). Evidence
points to the TGFβ pathway, where TGF-β1a n d- β3a r e
elevated in the serum cytokine proﬁle while TGF-β receptor
III (TGF-β RIII, β-glycan) and SMAD2 are over-expressed
in the GEP. The TGFβ pathway is known to cross-talk
with the WNT signaling pathway via Smads [35, 36].
TGFβ can also induce novel LEF-1 splice variants through
a Smad-independent signaling pathway [37].Therefore, in
CLL the expression and activation of LEF-1 may occur
through TGF β-Smad dependent or independent mecha-
nisms (Figure 3). Moreover, CLL cells respond abnormally
to TGFβ stimulation [38] and over-expression of TGF-βRIII
has been linked to over-expression of mutant K-ras [39].
Hence, it is conceivable that over-expression of RASGRF1
in CLL (Table 1)[ 40] may activate the MAP kinase pathway
leading to LEF-1 activation. Mikels and Nusse (2006) have
shown that when Ror-2 is expressed, Wnt5A [41]a n dm o r e
recently IGFBP-4 [42] have been shown to inhibit canonical
signalingdownstreamofβ-cateninstabilizationatthelevelof
TCF driven transcription. A similar mechanism may operate
in CLL where Ror-1 is expressed and an alternative pathway
activates LEF-1.
The study identiﬁed CXCL9-CXCR3 L-R pair where
CXCL9 levels are elevated in the serum and CXCR3 was
over-expressed in the GEP (Table 3(b)). CXCR3, a G-protein
coupled chemokine receptor is normally expressed on Th1
cells and its expression is associated with peripheral inﬂam-
mation. Th1 cells express CXCR3 during activation and
diﬀerentiation implying eﬀector functions in both central
andperipherallymphoidtissue[43].CLLcellshighlyexpress
CXCR3, which promotes eﬃcient migration in response to
CXCL9 in comparison to normal PB B-cells [27]. CXCL9
is coexpressed with CXCR3 in CLL [28] implicating an
autocrine mechanism of malignant B-cell activation and
promotion of migration (Figure 3). Interferon-γ (IFNγ) the
1st ranked elevated cytokine (Table 3(a)) in the cytokine
proﬁleisknowntoinduceCXCL9requiredforT-cellrecruit-
ment and eﬀector functions [44]. A similar mechanism may
operate in CLL cells.
Flt-3L is elevated in the serum cytokine proﬁle and
FLT-3 is over-expressed by GEP. RT-PCR analysis of 20
CLL patients conﬁrmed over-expression of FLT-3 (6-40
fold) in a subset of cases (40%) (Supplementary Figure
3). Flt-3 is constitutively activated due to internal tandem
duplication(ITD)mutationsinthejuxta-membranedomain
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( A M L )a n da c u t eB - c e l ll e u k e m i a( A L L )[ 29]. Kim K-T et
al., 2005 [45], demonstrated that PIM-1, a proto-oncogene
with serine/threonine kinase activity is signiﬁcantly down-
regulated when Flt-3 is inhibited with CEP-701, an Flt-3
tyrosine kinase inhibitor. A similar inhibitory eﬀect with
CEP-701 was also shown for BAD (Bcl-2 antagonist of cell
death) phosphorylation [45]. In our GEP, PIM-1 is over-
expressed while its substrates c-MYB, BCL11B, STAT4 and
CDC25B are also over-expressed. Pim-1 is known to be up-
regulated by stat 5, which is also a downstream target of
Flt-3 signaling. We propose that activated Flt-3 up-regulates
and activates Pim-1 kinase providing proliferative and anti-
apoptotic signals to some CLL cells.
Hemoglobin (HB) A and B are over-expressed in CLL
patients (Table 2(a)). Alpha and beta-globin RNA have been
detected in erythroid cells (fetal liver and reticulocytes) and
non-erythroid tissues (adult brain and liver, and cultured
lymphoma, untransformed, and transformed ﬁbroblast cell
lines) [46]. Reactive oxygen species (ROS) at physiological
concentrations are required for normal cell function but
excessive production of ROS is detrimental to cells. It has
been shown that treatment of HT-29 colon cancer cells
with HB enhanced proliferation via reactive oxygen species
(ROS) production and signiﬁcantly blunts the cytotoxic
eﬀects of 5-FU and 5-DFUR [47]. Papillary thyroid car-
cinomas (PTC) express HBB at similar levels to normal
thyroid gland but over-expression of HBB in KTA2 cells
(anaplastic thyroid cancer cell line), signiﬁcantly suppressed
their growth [48]. In CLL, there is progressive accumulation
of well diﬀerentiated malignant cells that are arrested in
G0/G1 and generation of excessive ROS in this setting would
be detrimental. Therefore, over-expression of HBA and HBB
may counter excessive ROS production and be protective to
CLL cells.
P53 and ZAP-70 are important markers of CLL patho-
genesis. We show that P53 expression is down regulated and
ZAP-70 is over-expressed in low stage CLL (Supplementary
Figure 4). When the white cell count or the absolute
lymphocyte count (ALC) was plotted against P53 or ZAP-70
level of expression, there is no signiﬁcant correlation. Hence,
the loss of P53 or gain of ZAP-70 function is independent
of disease burden, but may be related to initiation and
progression of the abnormal CLL clone.
CLLcellsareresistanttoapoptosisbutonceincellculture
appear to lose viability. Several diﬀerent approaches to
maintainCLLcellsinculturehavebeeninvestigatedbutnone
has been successfully implemented [49]. We hypothesize
that a major reason for inability to grow these cells is due
to the removal of a factor or factors from their natural
(plasma or serum) environment. We demonstrate that CLL
cells elaborate a chemokine-cytokine response to being in
culture at 24 hours. It is known that CLL cells regulate
the microenvironment through modulation of the cytokine
milieu that recruit and activate immune cells (T-cells). Since
standard culture conditions do not have access to accessory
survival mechanisms, these cells undergo apoptosis over a
period of 1-2 weeks.
Targeting of the tumor microenvironment with
immunomodulatory (iMiD) agents such as thalidomide
and lenalidomide has been evaluated in CLL [24]w i t h
promising clinical activity [50]. Thalidomide therapy in CLL
cells showed no cytotoxicity, and a similar result has been
reported for lenalidomide in in vitro tumor models of CLL
[24]. We also evaluated diﬀerential gene expression between
thalidomide untreated and treated CLL cells in culture for
24 hours and showed very modest gene expression changes.
This is consistent with its proposed mechanism of action
on the stroma and activation of the immune system rather
than a direct eﬀect on malignant cells. The lack of a direct
eﬀect of thalidomide on CLL cells in culture and activity in
patients implies a role for iMiDs in modulating the stromal
microenvironment for their therapeutic eﬃcacy.
5. Conclusion
Our study identiﬁed 3 novel diﬀerentially expressed onco-
genic pathways pertinent to low stage CLL patients. These
pathways are implicated aberrant regulation of cell prolifera-
tion, survival and migration of CLL cells. Further, in most
of the patients p53 is down-regulated while ZAP70 is up-
regulated suggesting a common mechanism of pathogenesis.
Interferonγ, Flt-3L and IGFBP4 are the most prominent
serum cytokines in low stage CLL with the latter implicated
in modulating the Wnt signaling pathway [51]. The 6
essential alterations in cell physiology that collectively dictate
malignant growth (CLL) are represented by 25–30 up-
regulated over-expressed cancer genes and down-regulated
tumor suppressors which appear to determine a slow
proliferator phenotype. This CLL phenotype has gained the
abilitytoavoidimmuneattackbyNKandT-cellsbysecreting
factors that inhibit eﬀector activity and appears to subvert
thebonemarrowstromalenvironmentforsurvival.Ourdata
provide a platform to extend these studies to high stage (Rai
III/IV) CLL patients. A recent GEP study of Waldenstrom
macroglobulinemia (WM) showed a phenotype similar to
CLL and PB B-cells than multiple myeloma [52] implicating
a small set of diﬀerentially expressed genes which may
distinguish between these lymphoproliferative diseases.
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